Global Cancer Targeted Therapy Market 2019 by Company, Regions, Type and Application, Forecast to 2024

SKU ID : GIR-GIR1902060326 13550652

Publishing Date : 12-Jun-2019

No. of pages : 135

PRICE
3480
6960



  • Scope of the Report:
    The global Cancer Targeted Therapy market is valued at million USD in 2018 and is expected to reach million USD by the end of 2024, growing at a CAGR of between 2019 and 2024.
    The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
    North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Cancer Targeted Therapy.
    Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
    This report studies the Cancer Targeted Therapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Cancer Targeted Therapy market by product type and applications/end industries.

    Market Segment by Companies, this report covers
    Advaxis
    Bind Therapeutics
    Boehringer Ingelheim
    Bristol Mayer Squibb
    Celldex Therapeutics
    Dendreon Corporation
    Eli Lily
    GalaxoSmithKline
    Galena Biopharma
    Genetech
    ImmunoCellular Therapeutics
    ImmunoGen
    Inovio Pharmaceuticals
    Johnson & Johnson
    NeoStem Oncology
    NewLink Genetics
    Northwest Biotherapeutics
    Merck
    Novartis
    Peregrine Pharmaceuticals
    Pfizer
    Roche
    Sanofi
    Seattle Genetics
    Teva

    Market Segment by Regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia and Italy)
    Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
    South America (Brazil, Argentina, Colombia)
    Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

    Market Segment by Type, covers
    Tumor Antigens As Targets of Antibodies
    Development of Antibodies for Clinical Purposes
    Complement Dependent Cytotoxicity (CDC)
    Signal Transduction Changes

    Market Segment by Applications, can be divided into
    Hospital
    Clinic
    Other